Import from "@/components/mdx"

MOTS-c and Sexual Function: What Women Need to Know About This Mitochondrial Peptide

What Is MOTS-c and Why Are Women Asking About It?

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 12-amino-acid peptide encoded not in the nuclear genome but inside the mitochondria itself. That origin is unusual. Most peptide hormones are nuclear-gene products; MOTS-c is one of a growing class called mitochondrial-derived peptides, or MDPs, that appear to act as metabolic stress signals between cells and organs.

Interest from women in the peri- and post-menopausal range has grown rapidly because MOTS-c research touches three overlapping concerns: declining energy metabolism after midlife hormonal shifts, insulin resistance that clusters around the menopause transition, and the downstream effects of those metabolic changes on sexual desire and arousal.

The peptide was first characterized in a landmark 2015 paper by Lee and colleagues in Cell Metabolism, which showed that MOTS-c injected into diet-induced obese mice improved insulin sensitivity and reduced fat accumulation. That single rodent study remains the most cited anchor for most of the clinical speculation you will encounter online. Understanding what it actually showed, and what it did not, matters before you consider any form of use.

How MOTS-c Works at a Cellular Level

MOTS-c is released by mitochondria in response to cellular stress, particularly glucose-related metabolic strain. Once secreted, it travels to the nucleus, where it modulates gene expression linked to the folate cycle and methionine metabolism, suppresses the pentose phosphate pathway, and activates AMPK, a master metabolic switch that governs energy balance across fat, muscle, and liver tissue.

AMPK activation is relevant to sexual function through at least two pathways. First, AMPK improves mitochondrial biogenesis, meaning more energy-producing capacity per cell. Vaginal mucosal tissue, clitoral smooth muscle, and genital sensory neurons are all metabolically demanding structures. Second, AMPK activity intersects with nitric oxide synthase pathways, which govern genital blood flow and, in women, lubrication and engorgement responses.

The Metabolic-Sexual Function Connection in Women

Metabolic dysfunction is one of the most under-recognized drivers of female sexual dysfunction. A 2021 cross-sectional study published in the Journal of Sexual Medicine found that women with type 2 diabetes had a significantly higher prevalence of female sexual dysfunction (FSD) compared with normoglycemic controls, with impaired arousal and lubrication being the most frequent complaints. Insulin resistance, even short of a diabetes diagnosis, disrupts androgen biosynthesis, blunts dopamine-driven desire pathways, and reduces nitric oxide availability in genital tissue.

If MOTS-c genuinely improves insulin sensitivity in humans at clinically meaningful doses, a downstream benefit to sexual function is biologically plausible. Plausible is not the same as proven.

The Actual Clinical Evidence for MOTS-c in Humans

The human data for MOTS-c is thin. That is not a criticism of the peptide; it reflects the very early stage of the research. Being honest about this is the most useful thing a clinician can tell you.

Animal and In Vitro Data

The 2015 Lee et al. Cell Metabolism study remains the foundational reference. Male and female mice were treated with synthetic MOTS-c at 15 mg/kg intraperitoneally. Treated animals showed reduced adiposity, improved glucose tolerance on an oral glucose tolerance test, and increased skeletal muscle insulin signaling via AKT phosphorylation. The researchers observed that endogenous MOTS-c levels declined with age and with high-fat diet feeding, suggesting it behaves as a longevity-related signal.

A follow-up from the same group, published in Nature Medicine (Kim et al., 2022), showed that MOTS-c expression increases in response to exercise in humans, with plasma levels rising acutely after aerobic activity. This exercise-response profile is consistent with MOTS-c acting as a physiological mediator of exercise-induced metabolic benefits, which has implications for women trying to understand whether supplemental MOTS-c offers anything beyond what structured physical activity already provides.

Human Observational Data

Zempo et al. (2021) published cross-sectional data in older adults showing that circulating MOTS-c concentrations were significantly lower in individuals with metabolic syndrome than in metabolically healthy controls. The sample included both sexes, but sex-stratified analysis was not presented in full, which is a recurring limitation in this literature. Circulating MOTS-c was positively associated with skeletal muscle mass index in this cohort, suggesting a muscle-protective or muscle-preserving signal.

No published randomized controlled trial has yet dosed MOTS-c in women and measured any sexual function outcome. That evidence gap is not an oversight in this article. The gap is real.

What "Clinical Update" Actually Means Right Now

As of mid-2025, the most current synthesis of MOTS-c human data comes from a 2024 review in Ageing Research Reviews, which concluded that MOTS-c's metabolic benefits in humans remain promising but unconfirmed at the level of adequately powered RCTs. The review noted particular uncertainty about optimal dosing, delivery route (subcutaneous vs. Intravenous), and tissue-specific pharmacokinetics in women versus men. The authors called for sex-disaggregated trial design as a priority.

A practical framework for interpreting MOTS-c claims: Grade A evidence would require at minimum one phase II RCT in humans with pre-specified sexual function endpoints using a validated instrument such as the Female Sexual Function Index (FSFI). Currently, MOTS-c sits at Grade C at best for any human application, meaning case series, mechanistic studies, or animal data only. Any provider or compounding pharmacy presenting MOTS-c as a sexual health treatment with clinical certainty is overstating what the data support.

MOTS-c and Female-Specific Physiology Across Life Stages

Reproductive Years (Ages 18-40)

During the reproductive years, sex hormone-binding globulin (SHBG), estradiol, and progesterone fluctuate with the menstrual cycle and exert direct effects on mitochondrial function. Estradiol upregulates mitochondrial biogenesis through estrogen receptor-beta (ERb) signaling in a pattern that is largely protective. MOTS-c and estradiol may share some downstream targets, but no study has mapped their interaction in cycling women.

Women with PCOS represent a subgroup where MOTS-c's insulin-sensitizing mechanism is particularly interesting. PCOS affects approximately 8-13% of reproductive-age women worldwide and is characterized by hyperinsulinemia, androgen excess, and impaired mitochondrial function in granulosa cells. If MOTS-c improves mitochondrial efficiency and reduces hyperinsulinemia, it could theoretically reduce androgen-driven sexual dysfunction, but this has not been tested in any PCOS-specific trial.

Perimenopause (Typically Ages 45-55)

Perimenopause is the life stage where MOTS-c's profile is most clinically relevant for sexual function. As estradiol levels become erratic and eventually decline, mitochondrial function in genital tissue deteriorates, AMPK activity decreases, and insulin sensitivity worsens. This is the stage where women most commonly report new-onset low libido, reduced arousal, and genitourinary syndrome of menopause (GSM).

The Menopause Society (formerly NAMS) 2023 position statement on hormone therapy names declining estrogen as the primary driver of GSM, which affects up to 45% of menopausal women. MOTS-c is not a substitute for estrogen therapy in this context. A woman experiencing GSM, reduced lubrication, or dyspareunia has effective, evidence-based options including local vaginal estrogen, ospemifene, or dehydroepiandrosterone (DHEA/prasterone) that have been studied in rigorous RCTs.

That context matters. Pursuing MOTS-c as a first-line sexual health intervention when established treatments exist would mean choosing a less-studied option over a better-studied one.

Post-Menopause (After Final Menstrual Period)

Post-menopausal women show measurably lower endogenous MOTS-c concentrations compared with premenopausal women in the Zempo (2021) dataset, though this comparison was not the paper's primary analysis. Whether this represents a causal pathway or a parallel decline alongside estrogen loss is unknown.

Post-menopausal women are also the most likely to have concurrent metabolic comorbidities (hypertension, type 2 diabetes, dyslipidemia) that complicate peptide use, interact with other medications, and increase the importance of having proper monitoring before any off-label peptide therapy.

Trying to Conceive

Women who are actively trying to conceive should not use MOTS-c. The peptide's effects on folliculogenesis, ovarian reserve, embryo implantation, or early placentation are entirely unknown. No animal reproductive toxicology studies in the peer-reviewed literature have been published. The absence of evidence of harm is not evidence of safety when you are considering the conceptus.

Pregnancy and Lactation Safety

MOTS-c is not approved for use in pregnancy or while breastfeeding. There is no human or animal reproductive toxicology data sufficient to characterize its risk.

Pregnancy

MOTS-c has no FDA pregnancy category because it is not an approved drug. No animal embryo-fetal development studies meeting ICH S5 standards have been published in peer-reviewed literature as of this writing. The peptide targets AMPK, mTOR signaling, and methionine cycle enzymes, all of which are critical regulators of early embryonic cell division and placental function. Disruption of these pathways carries theoretical teratogenic risk, though no data exist to quantify it.

If you discover you are pregnant while using MOTS-c from a compounding source, stop immediately and contact your OB-GYN or maternal-fetal medicine provider.

Lactation

MOTS-c's transfer into breast milk is unknown. Its 12-amino-acid structure means it is a small peptide that could theoretically pass into milk, though GI proteolysis would likely degrade most of it before systemic absorption in the infant. "Likely degraded" is not the same as "proven safe." Until lactation studies exist, the standard clinical recommendation is to avoid use while breastfeeding.

Contraception Requirement

Any woman of reproductive age using MOTS-c from a compounding pharmacy should use reliable contraception. Compounded peptides are not subject to the same manufacturing and safety monitoring as FDA-approved drugs. The combination of unknown teratogenicity risk and unregulated manufacturing creates a scenario where unintended pregnancy during use poses a distinct safety concern.

Who Might Consider MOTS-c and Who Should Not

Potentially Reasonable Candidates

Based on the existing mechanistic and early human data, the profile most aligned with MOTS-c's studied benefits is a woman who:

• Is post-menopausal or perimenopausal with documented insulin resistance or metabolic syndrome
• Has already optimized lifestyle factors (exercise, diet, sleep) and first-line medical treatments
• Has sexual dysfunction attributable at least partly to metabolic drivers rather than solely to estrogen deficiency
• Is working with a provider who can monitor metabolic labs, has transparent sourcing from a compounding pharmacy with third-party COA verification, and understands the investigational nature of this use

Women Who Should Not Use MOTS-c

• Women who are pregnant or breastfeeding (see above)
• Women trying to conceive
• Women with active autoimmune conditions, given MOTS-c's effects on immune signaling pathways through AMPK are incompletely characterized
• Women with a personal or family history of cancer until oncologic safety data exist, because AMPK modulation affects mTOR, a pathway relevant to tumor growth
• Women who have not first tried FDA-approved treatments for their primary concern (low libido, GSM, insulin resistance), because replacing proven options with unproven ones is not a sound clinical strategy

Dosing, Delivery, and What Compounding Pharmacies Are Offering

Because MOTS-c is not FDA-approved, there is no standard dose. Published animal studies used weights between 5-15 mg/kg intraperitoneally. Human extrapolation is not straightforward; interspecies scaling does not apply linearly to peptides with complex receptor-binding profiles.

Compounding pharmacies currently offering MOTS-c in the US typically provide subcutaneous injection vials in concentrations ranging from 5 mg to 10 mg per vial, with dosing protocols of 2-5 mg subcutaneously, two to five times per week. These protocols are derived from practitioner experience, not clinical trial data. Oral bioavailability of peptides of this length is extremely low; subcutaneous injection bypasses first-pass degradation.

The FDA has not approved any compounded MOTS-c product, and compounded peptides fall outside FDA manufacturing oversight unless the pharmacy is registered under specific categories. Always request a certificate of analysis (COA) from an independent third-party lab for purity, potency, and sterility before any injection.

The Evidence Gap: Women Are Underrepresented in MOTS-c Research

The published MOTS-c literature does not include a single RCT with a female-only cohort. Most mechanistic animal studies have used male mice or mixed-sex groups without sex-stratified reporting. This is not unique to MOTS-c; it reflects a decades-long pattern of under-representing female subjects in metabolic and longevity research, documented formally in the 2016 NIH policy requiring sex as a biological variable (SABV) in preclinical studies.

Sex differences in AMPK signaling, mitochondrial dynamics, and peptide pharmacokinetics are well-established in other contexts. Estrogen itself modulates AMPK activity. A woman's endogenous hormonal milieu could meaningfully alter how MOTS-c behaves at both the receptor and downstream signaling level. Whether the peptide works differently in a cycling 35-year-old versus a post-menopausal 60-year-old is a question the current literature cannot answer.

Assuming that male-derived or mixed-cohort data applies uniformly to women is the same kind of extrapolation that led to decades of cardiovascular guidelines written primarily from male trial data. The honest answer, repeated here deliberately: we do not know how MOTS-c behaves specifically in women, and any provider who tells you otherwise is working beyond what the evidence supports.

Comparing MOTS-c to Established Treatments for Female Sexual Dysfunction

Sexual dysfunction in women is complex and multi-factorial. Before considering an off-label investigational peptide, it is worth knowing what the evidence-based options are and what each addresses.

| Concern | Evidence-Based Option | Level of Evidence | |---|---|---| | Low libido (premenopausal) | Flibanserin (Addyi) | FDA-approved RCT data | | Low libido (post-menopausal) | Bremelanotide (Vyleesi), testosterone off-label | FDA-approved; testosterone supported by meta-analyses | | GSM / vaginal dryness | Local vaginal estrogen, prasterone, ospemifene | FDA-approved, multiple RCTs | | Insulin resistance affecting sexual function | Metformin, lifestyle, GLP-1 agonists | Strong RCT data for insulin sensitization | | PCOS-related dysfunction | Metformin, inositol, lifestyle | RCT data for metabolic endpoints | | MOTS-c for any sexual endpoint | No approved indication | Grade C: animal and mechanistic data only |

If you have low libido and your provider jumps immediately to MOTS-c without discussing the above options first, ask why. That is a reasonable clinical question.

What to Ask Your Provider

Considering MOTS-c with a provider who offers it? These are the specific questions worth raising in your appointment:

• What validated sexual function tool will you use to measure my outcome before and after (e.g., FSFI, FSDS-R)?
• Which metabolic labs will you check at baseline and during use (fasting insulin, HOMA-IR, fasting glucose, HbA1c, lipid panel)?
• Where is the peptide sourced, and can I see a third-party COA?
• What monitoring plan do you have for side effects, including injection site reactions and off-target immune effects?
• What is your stopping rule if I see no benefit at 12 weeks?

A provider who cannot answer these questions specifically should prompt caution.